The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC) (EpiC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06022328
Recruitment Status : Recruiting
First Posted : September 1, 2023
Last Update Posted : March 7, 2024
Sponsor:
Information provided by (Responsible Party):
University Hospital, Bordeaux

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.

Condition or disease Intervention/treatment
Myeloproliferative Neoplasm Biological: Assessment of the epigenetic age

Detailed Description:

Myeloproliferative Neoplasia (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. They include Essential Thrombocythemia (ET), Polycythemia Vera (VP) and Primary Myelofibrosis (PMF). Thrombosis are the most frequent complications and are largely responsible for the morbidity and mortality observed in ET and PV patients. The most feared complications are hematological transformations (into myelofibrosis for PV and ET, into acute myeloid leukemia for PV, ET and PMF). The prognostic assessment of MPN patients is mainly based on clinical data. Although recent studies have shown that certain mutations are associated with a poorer prognosis, age remains the main risk factor affecting survival in MPN patients. Recent studies have shown that DNA methylation can be used to determine an "epigenetic age". Interestingly, this epigenetic age is associated with the development of cardiovascular disease and cancer.

In this project, the epigenetic age of MPN patients will be determined by studying the DNA methylation at diagnosis using the Infinium Human MethylationEPIC kit (Illumina). Epigenetic age will be determined with the most commonly used epigenetic clocks (DNAmAge, DNAmHannum, DNAmPhenoAge, DNAmSkinClock, DNAmGrimAge, intrinsic epigenetic age acceleration, extrinsic epigenetic age acceleration). It will be searched for an association between accelerated epigenetic aging (as assessed by the difference between epigenetic age and chronological age) and the type of MPN, the clinical and biological presentation at diagnosis (including the mutational profile of patients) and the occurrence of thrombosis and hematological evolution into myelofibrosis and/or acute leukemia.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Actual Study Start Date : December 15, 2023
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients with ET

45 patients with ET:

  • 15 without thrombotic event (neither at diagnosis nor during follow-up)
  • 15 with thrombotic events (thrombosis at diagnosis or within 2 years of diagnosis)
  • 15 who progressed to myelofibrosis or AML during follow-up
 Biological: Assessment of the epigenetic age
Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
Patients with PV

45 patients with PV

  • 15 without thrombotic event (neither at diagnosis nor during follow-up)
  • 15 with thrombotic event (thrombosis at diagnosis or within 2 years of diagnosis)
  • 15 who progressed to myelofibrosis or AML during follow-up
 Biological: Assessment of the epigenetic age
Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
Patients with PMF

20 patients with PMF:

  • 10 without transformation into AML
  • 10 patients who progressed to AML
 Biological: Assessment of the epigenetic age
Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
Patients without MPN
10 patients without MPN
 Biological: Assessment of the epigenetic age
Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Accelerated ageing of patients [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Accelerated ageing will be defined as an increased difference between the epigenetic age (calculated from DNA methylation data with the different molecular clocks described: DNAmAge, DNAmHannum, DNAmPhenoAge, DNAmSkinClock, DNAmGrimAge, intrinsic epigenetic age acceleration, extrinsic epigenetic age acceleration) and the chronological age


Secondary Outcome Measures :
  1. Type of MPN (ET, PV or PMF) at diagnosis [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    We will study patients with a diagnosis of ET, PV or PMF as defined by the WHO classification of hematological malignancies

  2. Transformation into secondary myelofibrosis or acute leukemia [ Time Frame: From date of inclusion until documentation of the event, assessed up to 5 years ]
    Evolution toward secondary myelofibrosis or acute leukemia will be defined according to the WHO classification of hematological malignancies

  3. Occurrence of thrombosis prior to diagnosis or during follow-up of the disease [ Time Frame: Between 1 year before and 2 years after MPN diagnosis ]
    Occurrence of myocardial infarction, ischemic stroke, deep vein thrombosis, pulmonary embolism, splanchnic thrombosis or any other significant thrombosis. Tinnitus, vertigo, headaches, erythromelalgia as well as superficial vein thrombosis will not be considered as thrombotic events

  4. Leukocytes [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Leukocytes level on blood count in G/L

  5. Platelets [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Platelet level on blood count in G/L

  6. Granulocytes [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Granulocytes level on blood count in G/L

  7. Monocytes [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Monocytes level on blood count in G/L

  8. Hemoglobin [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Hemoglobin level on blood count in g/dL

  9. Hematocrit [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    Hematocrit level on blood count in %

  10. Additional somatic mutation [ Time Frame: At inclusion, up to 1 year after diagnosis ]
    In up to 50% of MPN patients, genetic variants can be detected in genes such as DNMT3A, TET2, ASXL1, SRSF2, SF3B1, U2AF1, EZH2 or TP53. We will determine which somatic genetic variant is detected by high throughput sequencing


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Myeloproliferative Neoplasia (MPN) : Essential Thrombocythemia (ET), Polycythemia Vera (VP) or Primary Myelofibrosis (PMF)
Criteria

Inclusion Criteria:

For the 110 patients with MPN:

  • Patients with PV, ET or PMF
  • DNA extracted from purified granulocytes at time of diagnosis
  • No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)

For the 10 subjects without MPN:

  • Absence of hematological malignancy
  • Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia
  • Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)

Exclusion Criteria:

For the 110 patients with MPN:

  • Patients without PV, ET or PMF
  • Patients without purified granulocytes DNA available at time of diagnosis
  • Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
  • Patients with less than 2 years' follow-up

For the 10 subjects in NMP :

  • Patients with hematological malignancy and/or solid cancer
  • Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06022328


Contacts
Layout table for location contacts
Contact: Olivier MANSIER olivier.mansier@chu-bordeaux.fr

Locations
Layout table for location information
France
CHU de Bordeaux, service Hématologie Biologique Recruiting
Bordeaux, France
Contact: Olivier MANSIER       olivier.mansier@chu-bordeaux.fr   
Sponsors and Collaborators
University Hospital, Bordeaux
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT06022328    
Other Study ID Numbers: CHUBX 2023/15
First Posted: September 1, 2023    Key Record Dates
Last Update Posted: March 7, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Bordeaux:
Myeloproliferative Neoplasm
Epigenetic age
Thrombosis
Myelofibrosis
Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases